Colombian biodiversity, an opportunity for the strengthening of the pharmaceutical and cosmetic industries
DOI:
https://doi.org/10.17533/udea.vitae.v23n3a01Abstract
Colombia, a country privileged by nature, where diversity of climates are created by large altitude gradients which generate a variety of ecosystems and beautiful badlands, punas, mountain forests, dry valleys, high deserts and salt flats; landscapes that have diversity of plants and animals and we are cata- loged as one of the countries as the greatest diversity in the world, preceded by Brazil and followed by Indonesia, China and Mexico. We have 28.000 plants and lichens; it is an invaluable heritage that can give to our country competitive advantages in the discovery and development of active ingredients for the pharmaceutical and cosmetic industry by sustainable use of our biodiversity.
Downloads
References
Bernal R, S. R. Gradstein, M. Celis. Catálogo de plantas y líquenes de Colombia [Internet]. Instituto de Ciencias Naturales, Universidad Nacional de Colombia. 2015. Available from: http://catalogoplantasdecolombia.unal.edu.co/es/resultados/especie/Ugni myricoides/
Saintemarie A, Matic N. In-cosmetics [Internet]. The Global Natural and Organic Cosmetics Market. 2015 [cited 2015 Dec 2]. Available from: http://www.in-cosmetics.com/RXUK/RXUK_InCosmetics/2015-Website/Documents/in-cos15, D2, The race to outpace The global natural and organic cosmetics market, Agnieszka Saintemarie.pdf?v=635651392568408092
María Elena Ayala. Análisis de Competitividad Internacional del Sector Cosméticos e Ingredientes Naturales [Internet]. 2015 [cited 2016 Aug 26]. Available from: https://www.ptp.com.co/documentos/Analisis de competitividad internacional.pdf
Procolombia. Colombia, tras el mercado mundial de cosméticos y productos de aseo [Internet]. 2014 [cited 2016 Feb 15]. Available from: http://www.procolombia.co/noticias/colombia-tras-el-mercado-mundial-de-cosmeticos-y-productos-de-aseo
Fleming A. On the antibacterial action of cultures of Penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 1929 10, 226–236 (1929).
Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013 Jun;1830(6):3670-95.
McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM (1982). Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch. Biochem. Biophys. Oct; 218(1): 329-34.
Kingston DG. Modern natural products drug discovery and its relevance to biodiversity conservation. J Nat Prod. 2011 Mar 25;74(3):496-511.
Ondetti M A, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry. 1971 Oct; 10(22): 4033-9.
Pereañez JA, Patiño AC, Henao Castañeda IC. Toxinas provenientes de venenos de serpiente: blancos terapéuticos, herramientas en investigación biomédica y agentes con potencial terapéutico. Curare 2014; 1(1): 49-60.
Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon 2012 Mar; 59: 464–71.
Debotton N, Dahan A. Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms. Med Res Rev. 2016 Aug 9. doi: 10.1002/med
Downloads
Published
How to Cite
Issue
Section
License
Copyright Notice and Open Access Statement
The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.
Authors declare that:
-
They are the intellectual property owners and are responsible for all the information stated in the article.
-
This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.
-
They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.
-
They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.
-
Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.
-
They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.
-
They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.
-
They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.
-
After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.
Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.
